At present, multiple myeloma (MM) is still incurable, and relapse or refractory are the main clinical problems. In addition to hematopoietic stem cell transplantation (HSCT) and chimeric antigen receptor T cell (CAR-T) immunotherapy, a variety of new drugs based on different mechanisms and their combination regimens continue to emerge, which provide a new option for the treatment of relapsed/refractory MM (RRMM). In order to further explore the drug treatment regimens for RRMM, this article reviews literatures on new drugs emerged in recent years, which were few in clinical applications or ongoing clinical studies in China.
